Last reviewed · How we verify
NCT06262919
Special Drug Use-results Surveillance of Tafinlar/Mekinist
trial testing Tafinlar/Mekinist in BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor in 110 participants. Currently enrolling.
31 December 2031
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 110 |
| Start date | 9 February 2024 |
| Primary completion | 31 December 2031 |
| Estimated completion | 31 December 2031 |
| Sites | 68 locations across Japan |
Drugs / interventions tested
- Tafinlar/Mekinist — full drug profile →
Conditions studied
- BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor — all drugs for BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
Adults 6 to 99, any sex, with BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, multicenter, single-arm, non-interventional and observational J-PMS conducted by the central registration system and operated in Electronic data capture.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06262919
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06262919 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 30 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06262919.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing